Henry Ford Hospital Medical Journal


There is evidence that renal cell carcinoma can alter the host immunologic system in several modalities. Diagnostic immunologic monitoring techniques reviewed in this report include delayed cutaneous hypersensitivity reaction (DCHR), absolute peripheral lymphocyte count (APLC), lymphocyte mitogen response (LMR), T-lymphocyte population (erythrocyte rosette), microcytotoxicity assay, in vitro monocyte chemotaxis, and serum blocking factors. Therapeutic immunologic modalities include xenogeneic immune ribonucleic acid (RNA), intradermal BCG, preoperative transcatheter renal artery embolization, immune plasma transfusion, transfer factor, and polymerized autologous tumor.